BioSpace News Archive

Company flexes infrastructure, collaborates even more transparently with provider partners to drive impact during pandemic

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Chief Financial Officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported preliminary EU field trial performance data for its MosaiQ Expanded Immunohematology (IH) Microarray.

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $60,000,000 of shares of its common stock.

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved a new employment inducement grant of stock

AGC Biologics announced that it will increase the production capacity of its Copenhagen facility.

Spero Therapeutics, Inc. announced that on November 30, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 76,200 shares of its common stock to ten new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan.

Ipsen (Euronext: IPN; ADR: IPSEY) today announced the United States Food and Drug Administration (FDA) has granted the company Fast Track designation for irinotecan liposome injection (ONIVYDE®) in study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen, reflecting the unmet medical need

Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a pre-clinical stage biotechnology company using its proprietary DIAMOND® artificial intelligence (“A.I.”) platform to improve drug discovery and development with a therapeutic focus on immune-oncology, today announced its financial results for the third quarter ended September 30, 2020, and provided an update on its corporate developments.

While the coronavirus pandemic brought unforeseen global challenges in 2020, the psychedelic renaissance repeatedly garnered historic victories.